$BST

BlackRock Science and Technology Trust's Dividend Analysis

BlackRock Science and Technology Trust (BST) announced a $0.25 per share dividend, payable November 30, 2026. The closed-end fund, managed by BlackRock, invests in tech sector equities and has increased dividends annually since 2015. BST offers a 6.26% yield, 7.10% 5-year growth, and a 0.17 payout ratio. Its profitability and growth ranks are 9/10, with revenue growing 55.50% annually. Investors should monitor portfolio performance and distribution composition.

Original reporting
Published Oct 15, 2026, 10:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 10:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$BST
Bullish
medium confidence
Mentioned
$BST
Relevance
5/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$BSTBullishMed
01

Why it matters

The dividend announcement confirms a stable income stream, which may support the fund's price in the short term.

02

Market read

Provides a fresh data point for income investors; modest price effect expected.

03

What to watch

Potential impact of rising interest rates on high‑yield closed‑end funds and the fund's exposure to cyclical tech stocks.

Relevance 5/10Novelty 6/10Timing: ahead of the November 30, 2026 payout

Background

BST is a closed‑end management investment company that provides exposure to large‑cap science and technology equities and distributes monthly income.

Company-level read

Ticker impact

$BSTBullishMedium confidence
Context

BST announced a $0.25 per share cash dividend with ex‑date Nov 13, 2026 and payment on Nov 30, 2026.

Expected impact

likely modest upside as the market prices in the confirmed dividend

Evidence & confidence

Dividend amount is modest but the fund's high yield and low payout ratio suggest sustainability, supporting a small price lift.

Market effects

reinforces the attractiveness of high‑yield tech‑focused closed‑end funds in a low‑rate environment

U.S. income‑seeking investors may shift allocation toward BST

limited to dividend‑focused investors; no broader macro impact

Counterpoint

The fund's leverage and tech concentration could outweigh the dividend appeal, leading to potential downside if market volatility rises.

Key entities

  • BlackRock Science and Technology Trust

    Closed‑end fund (ticker BST) focused on tech equities.

Related articles

$MIRMMed

Stifel raises Mirum Pharmaceuticals stock price target on approvals

Stifel raised its price target for Mirum Pharmaceuticals (MIRM) to $156 from $136, citing recent clinical and regulatory achievements. The stock trades at $82.64, with strong revenue growth of 44% over the last year, reaching $618 million. Analysts highlight multiple expansion opportunities and a potential peak portfolio value of over $4 billion. The stock has declined 17% over the past six months, but analysts maintain a positive outlook.

$TMLow

Toyota’s AU$750M DPF Payout: What HiLux, Prado and Fortuner Owners Get

Toyota Australia agreed to a AU$750 million settlement for class actions over diesel particulate filter (DPF) issues in HiLux, Prado, and Fortuner models, pending court approval. The settlement covers 264,170 vehicles sold between 2015 and 2020, with defects reducing vehicle value. Toyota Motor Corporation stated the payout is immaterial to its finances.

$KRYSMedAI 8/10

Krystal Biotech Reports KB113 Lesion Regression in Gorlin Syndrome Pilot Study as FDA Discussions Begin

Krystal Biotech (NASDAQ:KRYS) reported that its investigational immunotherapy KB113 showed regression in 83% of assessed basal cell carcinoma lesions in a pilot study of three Gorlin syndrome patients. The company has begun FDA discussions for further development. Biopsies confirmed complete responses in three lesions. The study is small and preliminary, with larger trials needed to confirm efficacy and safety.